Literature DB >> 22750233

Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?

Leon Caly1, Kylie M Wagstaff, David A Jans.   

Abstract

A key aspect of the infectious cycle of many viruses is the transport of specific viral proteins into the host cell nucleus to perturb the antiviral response. Examples include a number of RNA viruses that are significant human pathogens, such as human immunodeficiency virus (HIV)-1, influenza A, dengue, respiratory syncytial virus and rabies, as well agents that predominantly infect livestock, such as Rift valley fever virus and Venezuelan equine encephalitis virus. Inhibiting the nuclear trafficking of viral proteins as a therapeutic strategy offers an attractive possibility, with important recent progress having been made with respect to HIV-1 and dengue. The results validate nuclear protein import as an antiviral target, and suggest the identification and development of nuclear transport inhibitors as a viable therapeutic approach for a range of human and zoonotic pathogenic viruses.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22750233     DOI: 10.1016/j.antiviral.2012.06.008

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  39 in total

1.  Targeting Importin-α7 as a Therapeutic Approach against Pandemic Influenza Viruses.

Authors:  Patricia Resa-Infante; Duncan Paterson; Jaume Bonet; Anna Otte; Baldo Oliva; Ervin Fodor; Gülsah Gabriel
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

2.  Potential therapeutic effects of Ivermectin in COVID-19.

Authors:  Nastaran Barati; Seyedmousa Motavallihaghi; Banafsheh Nikfar; Shahla Chaichian; Amir Abbas Momtazi-Borojeni
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-10

Review 3.  Ivermectin: An Anthelmintic, an Insecticide, and Much More.

Authors:  Richard J Martin; Alan P Robertson; Shivani Choudhary
Journal:  Trends Parasitol       Date:  2020-11-11

4.  Selective Targeting of the TPX2 Site of Importin-α Using Fragment-Based Ligand Design.

Authors:  Rhian S Holvey; Eugene Valkov; David Neal; Murray Stewart; Chris Abell
Journal:  ChemMedChem       Date:  2015-04-20       Impact factor: 3.466

5.  A viral-human interactome based on structural motif-domain interactions captures the human infectome.

Authors:  Aldo Segura-Cabrera; Carlos A García-Pérez; Xianwu Guo; Mario A Rodríguez-Pérez
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

6.  Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import.

Authors:  Veronika Götz; Linda Magar; Dominik Dornfeld; Sebastian Giese; Anne Pohlmann; Dirk Höper; Byung-Whi Kong; David A Jans; Martin Beer; Otto Haller; Martin Schwemmle
Journal:  Sci Rep       Date:  2016-03-18       Impact factor: 4.379

Review 7.  Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.

Authors:  Safaet Alam; Taslima Binte Kamal; Md Moklesur Rahman Sarker; Jin-Rong Zhou; S M Abdur Rahman; Isa Naina Mohamed
Journal:  Front Pharmacol       Date:  2021-06-14       Impact factor: 5.810

8.  Bridging HIV-1 cellular latency and clinical long-term non-progressor: an interactomic view.

Authors:  Jin Yang; Zongxing Yang; Hangjun Lv; Yi Lou; Juan Wang; Nanping Wu
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

9.  Regulated transport into the nucleus of herpesviridae DNA replication core proteins.

Authors:  Alvisi Gualtiero; David A Jans; Daria Camozzi; Simone Avanzi; Arianna Loregian; Alessandro Ripalti; Giorgio Palù
Journal:  Viruses       Date:  2013-09-16       Impact factor: 5.048

Review 10.  Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions.

Authors:  James Whitehorn; Sophie Yacoub; Katherine L Anders; Louis R Macareo; M Cristina Cassetti; Vinh Chau Nguyen Van; Pei-Yong Shi; Bridget Wills; Cameron P Simmons
Journal:  PLoS Negl Trop Dis       Date:  2014-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.